2025-05-15 - Analysis Report
Okay, here's the analysis of TEVA, incorporating the provided data and following your instructions:

**Report: Teva Pharmaceutical Industries Ltd ADR (TEVA) Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Company Overview:** Teva Pharmaceutical Industries Ltd ADR is a global pharmaceutical company focused on generic and specialty medicines.
*   **TEVA Cumulative Return:** 0.0
*   **VOO Cumulative Return:** 0.0
*   **Relative Performance:**
    *   Max Divergence: 0.0
    *   Min Divergence: 0.0
    *   Current Divergence: 0.0
    *   Relative Divergence Position: 0.0

    (Note: Since both cumulative returns are 0.0, all divergence measures are also 0.0.  Meaningful interpretation requires actual return data.)

*   **Alpha/Beta Analysis:**

    | Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
    |------------|------|------|-------|------|-------|
    | 2015-2017  | 0.0% | 0.0% | 0.0% | 1.0 | 21.8 |
    | 2016-2018  | 0.0% | 0.0% | 0.0% | 1.0 | 17.7 |
    | 2017-2019  | 0.0% | 0.0% | 0.0% | 1.0 | 11.2 |
    | 2018-2020  | 0.0% | 0.0% | 0.0% | 1.0 | 11.1 |
    | 2019-2021  | 0.0% | 0.0% | 0.0% | 1.0 | 9.2 |
    | 2020-2022  | 0.0% | 0.0% | 0.0% | 1.0 | 10.5 |
    | 2021-2023  | 0.0% | 0.0% | 0.0% | 1.0 | 12.0 |
    | 2022-2024  | 0.0% | 0.0% | 0.0% | 1.0 | 25.3 |
    | 2023-2025  | 0.0% | 0.0% | 0.0% | 1.0 | 19.3 |

    **Analysis:** The table presents historical performance metrics. Notably, Alpha is consistently 0.0, indicating no outperformance relative to the market (VOO) during these periods. Beta is consistently 1.0, suggesting that TEVA's price movements have historically mirrored the market.  CAGR and MDD are 0.0%, which require actual data.  The "Cap(B)" column shows the market capitalization in billions for each period.

**2. Recent Price Action**

*   **Current Price:** 16.815
*   **Last Market Data:** Price: 16.835, Previous Close: 17.48, Change: -3.69%
*   **Moving Averages:**
    *   5-day: 17.475
    *   20-day: 15.4838
    *   60-day: 15.5761

    **Analysis:** The price has decreased by 3.69% in the most recent market session. The current price is below the 5-day moving average, but above both the 20-day and 60-day moving averages. This suggests a potential short-term downward trend, but the longer-term trend may still be positive or consolidating.

**3. Technical Indicators**

*   **Market Risk Indicator (MRI):** 0.0 (Outside typical ranges - requires actual data to be useful.)
*   **RSI:** 66.2379 (Approaching overbought territory.)
*   **PPO:** 1.7259 (Positive, suggesting short-term price strength.)
*   **Recent Relative Divergence Change (20-day):** 0.0 (Neutral, requires actual data to be useful.)
*   **Expected Return (%):** 0.0 (Requires actual data to be useful. Represents the projected excess return over the S&P 500 for a long-term investment.)
*   **Change Reflection:** The price change of -3.69% is relatively large, indicating a significant negative market reaction. This should be considered a potential short-term negative catalyst.

**4. Recent News & Significant Events**

*   **2025-05-11 to 2025-05-15:** Recent news indicates potential business developments, regulatory changes, and market events influencing TEVA's stock. Analysts are discussing performance in the context of industry trends and economic factors. The stock has shown notable volatility. Experts advise monitoring news and company announcements.

    **Analysis:** The news highlights a period of uncertainty and change surrounding TEVA. Volatility is present, and investors should closely follow developments.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출      |
|------------|-------|-----------|
| 2025-05-07 | 0.19  | 3.89 B$   |
| 2024-11-06 | -0.39 | 4.33 B$   |
| 2024-07-31 | -0.75 | 4.16 B$   |
| 2024-05-08 | -0.12 | 3.82 B$   |
| 2025-05-07 | -0.12 | 3.82 B$   |

**Analysis:** The data reveals a mixed earnings performance.  While the most recent EPS is positive (0.19), prior quarters showed losses. Revenue has fluctuated, ranging from $3.82B to $4.33B. The inconsistent profitability is a concern.

**6. Financial Information**

*   **Revenue and Profitability:**

    | Quarter      | Revenue   | Profit Margin |
    |--------------|-----------|---------------|
    | 2025-03-31   | $3.89B    | 48.24%        |
    | 2024-12-31   | $4.23B    | 50.15%        |
    | 2024-09-30   | $4.33B    | 49.60%        |
    | 2024-06-30   | $4.16B    | 48.61%        |
    | 2024-03-31   | $3.82B    | 46.37%        |

*   **Capital and Profitability:**

    | Quarter      | Equity   | ROE    |
    |--------------|----------|--------|
    | 2025-03-31   | $6.26B   | 3.42%  |
    | 2024-12-31   | $5.37B   | -4.04% |
    | 2024-09-30   | $6.07B   | -7.21% |
    | 2024-06-30   | $6.36B   | -13.30%|
    | 2024-03-31   | $7.28B   | -1.91% |

    **Analysis:** Revenue has been relatively consistent over the past year. Profit margins are healthy, ranging from 46% to 50%. However, the Return on Equity (ROE) has been volatile, with recent quarters showing negative values before turning positive in the most recent quarter. This requires investigation to determine the causes of the ROE fluctuations and their implications for future profitability.

**7. Overall Summary & Conclusion**

TEVA presents a mixed picture.

*   **Negatives:** Recent price decline, recent news indicating volatility and uncertainty, inconsistent earnings performance (especially negative EPS in some quarters), and volatile ROE.
*   **Positives:** Relatively consistent revenue, high profit margins, and a recent return to positive EPS and ROE.

**Recommendation:** Due to the recent negative price action and uncertainties surrounding TEVA, a cautious approach is warranted. Investors should closely monitor news, earnings reports, and further developments in the pharmaceutical industry and global economy. Additional research is necessary to understand the drivers behind the ROE volatility and recent changes in the MRI.
